A Comparison of Sertraline-Reboxetine Combination Therapy Versus Sertraline or Reboxetine Monotherapy in the Treatment of Major Depression.
Information source: Pfizer
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Depressive Disorder, Major
Intervention: sertraline/[S,S]-reboxetine (Drug); sertraline/[S,S]-reboxetine (Drug); sertraline (Drug); sertraline (Drug); sertraline/[S,S]-reboxetine (Drug); Placebo (Drug); sertraline/[S,S]-reboxetine (Drug); [S,S]-reboxetine monotherapy (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: Pfizer Official(s) and/or principal investigator(s): Pfizer CT.gov Call Center, Study Director, Affiliation: Pfizer
Summary
This study was designed to determine if the novel combination of the SSRI, sertraline, and
the NRI reboxetine will increase antidepressant efficacy without sacrificing the favorable
safety profile of SSRIs.
Clinical Details
Official title: Sertraline/[S,S]-Reboxetine Combination Versus Sertraline And [S,S]-Reboxetine Monotherapy In Major Depressive Disorder (MDD) In A Double-Blind, Placebo-Controlled, Eight Week Study.
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Primary outcome: The change from Baseline up to Week 8 (Visit 9) in the Montgomery-Asberg Depression Rating Scale (MADRS) total score as measured by a mixed concentration, suicidal ideation and restlessness.
Secondary outcome: Change from Baseline in HAM-D (17-item) total scoreChange from Baseline in the Hamilton Anxiety Rating Scale (HAM-A) and Apathy Evaluation Scale (AES) The frequency and severity of treatment-emergent adverse events, ECG changes, laboratory and vital signs changes by treatment group using descriptive statistics. Change from Baseline in MADRS total score
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Subjects must fulfill the criteria for MDD without psychotic features as defined by
DSMIV, based on clinical assessment and confirmed by Structural Clinical Interview
for DSM-IV Axis I Disorder-Clinical Version (SCID-I) plus the MDD Specifiers included
in the Research Version of SCID-I.
- HAM-D (17-item) ≥ 22 at Screening (Visit 1) and > 20 at Baseline (Visit 2).
- Minimum CGI-S ≥ 4 at Screening (Visit 1) and at Baseline (Visit 2).
Exclusion Criteria:
- Known failure to satisfactory respond after adequate dose and duration (12 weeks) of
treatment with clomipramine and one SSRI, or with two or more SSRIs.
- Subjects with > 20% HAM-D (17-item) improvement (decrease) from Screening (Visit 1)
at Baseline (Visit 2).
- Subjects with uncorrected hypothyroidism or hyperthyroidism.
Locations and Contacts
Pfizer Investigational Site, Pärnu 80012, Estonia
Pfizer Investigational Site, Tallinn 10614, Estonia
Pfizer Investigational Site, Tartu 51008, Estonia
Pfizer Investigational Site, Kazan 420012, Russian Federation
Pfizer Investigational Site, Moscow 107076, Russian Federation
Pfizer Investigational Site, Moscow 115522, Russian Federation
Pfizer Investigational Site, Moscow 119034, Russian Federation
Pfizer Investigational Site, Moscow 127473, Russian Federation
Pfizer Investigational Site, Moscow, Russian Federation
Pfizer Investigational Site, Rostov On Don 344010, Russian Federation
Pfizer Investigational Site, Smolensk 214019, Russian Federation
Pfizer Investigational Site, St Petersburg 190121, Russian Federation
Pfizer Investigational Site, St. Petersburg 192019, Russian Federation
Pfizer Investigational Site, St. Petersburg 193167, Russian Federation
Pfizer Investigational Site, St. Petersburg 194214, Russian Federation
Pfizer Investigational Site, Tomsk 634014, Russian Federation
Pfizer Investigational Site, Moscow, Russia, Russian Federation
Pfizer Investigational Site, St. Petersburg, Russia 192019, Russian Federation
Pfizer Investigational Site, Viljandi, Viljandi mk. 71024, Estonia
Additional Information
To obtain contact information for a study center near you, click here.
Starting date: June 2004
Last updated: April 3, 2008
|